Pharmacologic Inhibition of CXCL10 in Combination with Anti-Malarial Therapy Eliminates Mortality Associated with Murine Model of Cerebral Malaria

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wilson, Nana O ^a   Solomon, Wesley ^a   Anderson, Leonard ^a   Patrickson, John ^a   Pitts, Sidney ^a   Bond, Vincent ^a   Liu, Mingli ^a   Stiles, Jonathan K ^a  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; ATORVASTATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PLACEBO; VASCULOTROPIN; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; CASPASE; HEME OXYGENASE 1; HEPTANOIC ACID DERIVATIVE; HMOX1 PROTEIN, MOUSE; MEMBRANE PROTEIN; PYRROLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIMALARIAL ACTIVITY; APOPTOSIS; ARTICLE; BRAIN BLOOD VESSEL; BRAIN MALARIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; EXPERIMENTAL MOUSE; GENE OVEREXPRESSION; GLIA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MORTALITY; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SURVIVAL RATE; VASCULARIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD BRAIN BARRIER; C57BL MOUSE; CELL COUNT; CHEMICAL STRUCTURE; CONFORMATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; DRUG INTERACTION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; GLIA; IMMUNOLOGY; LEUKOCYTE; MALARIA, CEREBRAL; METABOLISM; PATHOLOGY; SURVIVAL;

ANIMALS; ANTIMALARIALS; APOPTOSIS; ARTEMISININS; BLOOD-BRAIN BARRIER; CASPASES; CELL COUNT; CHEMOKINE CXCL10; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; HEME OXYGENASE-1; HEPTANOIC ACIDS; HUMANS; LEUKOCYTES; MALARIA, CEREBRAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; NEUROGLIA; NUCLEIC ACID CONFORMATION; PYRROLES; SURVIVAL ANALYSIS;

EID: 84875929194     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060898     Document Type: Article

References (179)

1. World Health Organization (2012) World Malaria Report 2011.
2. Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, et al. (2010) Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376: 1647-1657.
3. Idro R, Marsh K, John CC, Newton CR, (2010) Cerebral malaria: mechanisms of brain injury and strategies for improved neurocognitive outcome. Pediatr Res 68: 267-274.
4. Idro R, Kakooza-Mwesige A, Balyejjussa S, Mirembe G, Mugasha C, et al. (2010) Severe neurological sequelae and behaviour problems after cerebral malaria in Ugandan children. BMC Res Notes 3: 104.
5. John CC, Bangirana P, Byarugaba J, Opoka RO, Idro R, et al. (2008) Cerebral malaria in children is associated with long-term cognitive impairment. Pediatrics 122: e92-e99.
6. Dondorp A, Nosten F, Stepniewska K, Day N, White N, (2005) Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366: 717-725.
7. Higgins SJ, Kain KC, Liles WC, (2011) Immunopathogenesis of falciparum malaria: implications for adjunctive therapy in the management of severe and cerebral malaria. Expert Rev Anti Infect Ther 9: 803-819.
8. Langhorne J, Buffet P, Galinski M, Good M, Harty J, et al. (2011) The relevance of non-human primate and rodent malaria models for humans. Malar J 10: 23.
9. Hunt NH, Grau GE, Engwerda C, Barnum SR, van der HH, et al. (2010) Murine cerebral malaria: the whole story. Trends Parasitol 26: 272-274.
10. Riley EM, Couper KN, Helmby H, Hafalla JC, de Souza JB, et al. (2010) Neuropathogenesis of human and murine malaria. Trends Parasitol 26: 277-278.
11. Carvalho LJ, (2010) Murine cerebral malaria: how far from human cerebral malaria? Trends Parasitol 26: 271-272.
12. de Souza JB, Hafalla JC, Riley EM, Couper KN, (2010) Cerebral malaria: why experimental murine models are required to understand the pathogenesis of disease. Parasitology 137: 755-772.
13. White NJ, Turner GD, Medana IM, Dondorp AM, Day NP, (2010) The murine cerebral malaria phenomenon. Trends Parasitol 26: 11-15.
14. Engwerda C, Belnoue E, Gruner AC, Renia L, (2005) Experimental models of cerebral malaria. Curr Top Microbiol Immunol 297: 103-143.
15. Franke-Fayard B, Janse CJ, Cunha-Rodrigues M, Ramesar J, Buscher P, et al. (2005) Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is unlinked to sequestration. Proc Natl Acad Sci U S A 102: 11468-11473.
16. Lamb TJ, Brown DE, Potocnik AJ, Langhorne J, (2006) Insights into the immunopathogenesis of malaria using mouse models. Expert Rev Mol Med 8: 1-22.
17. Lou J, Lucas R, Grau GE (2001) Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans.Clin Microbiol Rev 14:810- 20, table.
18. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, et al. (2007) Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med 13: 703-710.
19. Renia L, Potter SM, Mauduit M, Rosa DS, Kayibanda M, et al. (2006) Pathogenic T cells in cerebral malaria. Int J Parasitol 36: 547-554.
20. Brown H, Turner G, Rogerson S, Tembo M, Mwenechanya J, et al. (1999) Cytokine expression in the brain in human cerebral malaria. J Infect Dis 180: 1742-1746.
21. Nacer A, Movila A, Baer K, Mikolajczak SA, Kappe SH, et al. (2012) Neuroimmunological blood brain barrier opening in experimental cerebral malaria. PLoS Pathog 8: e1002982.
22. Mackey LJ, Hochmann A, June CH, Contreras CE, Lambert PH, (1980) Immunopathological aspects of Plasmodium berghei infection in five strains of mice. II. Immunopathology of cerebral and other tissue lesions during the infection. Clin Exp Immunol 42: 412-420.
23. Cox D, McConkey S, (2010) The role of platelets in the pathogenesis of cerebral malaria. Cell Mol Life Sci 67: 557-568.
24. Craig AG, Grau GE, Janse C, Kazura JW, Milner D, et al. (2012) The role of animal models for research on severe malaria. PLoS Pathog 8: e1002401.
25. Zimmerman GA, Castro-Faria-Neto H, (2010) Persistent cognitive impairment after cerebral malaria: models, mechanisms and adjunctive therapies. Expert Rev Anti Infect Ther 8: 1209-1212.
26. Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, et al. (2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog 5: e1000369.
27. Faille D, El-Assaad F, Alessi MC, Fusai T, Combes V, et al. (2009) Platelet-endothelial cell interactions in cerebral malaria: the end of a cordial understanding. Thromb Haemost 102: 1093-1102.
28. Faille D, Combes V, Mitchell AJ, Fontaine A, Juhan-Vague I, et al. (2009) Platelet microparticles: a new player in malaria parasite cytoadherence to human brain endothelium. FASEB J 23: 3449-3458.
29. Haldar K, Murphy SC, Milner DA, Taylor TE, (2007) Malaria: mechanisms of erythrocytic infection and pathological correlates of severe disease. Annu Rev Pathol 2: 217-249.
30. Grau GE, Mackenzie CD, Carr RA, Redard M, Pizzolato G, et al. (2003) Platelet accumulation in brain microvessels in fatal pediatric cerebral malaria. J Infect Dis 187: 461-466.
31. McElroy PD, Beier JC, Oster CN, Onyango FK, Oloo AJ, et al. (1997) Dose- and time-dependent relations between infective Anopheles inoculation and outcomes of Plasmodium falciparum parasitemia among children in western Kenya. Am J Epidemiol 145: 945-956.
32. Day NP, Hien TT, Schollaardt T, Loc PP, Chuong LV, et al. (1999) The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis 180: 1288-1297.
33. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot-Olupot P, et al. (2011) Mortality after fluid bolus in African children with severe infection. N Engl J Med 364: 2483-2495.
34. John CC, Kutamba E, Mugarura K, Opoka RO, (2010) Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther 8: 997-1008.
35. Mishra SK, Newton CR, (2009) Diagnosis and management of the neurological complications of falciparum malaria. Nat Rev Neurol 5: 189-198.
36. Wilson NO, Jain V, Roberts CE, Lucchi N, Joel PK, et al. (2011) CXCL4 and CXCL10 predict risk of fatal cerebral malaria. Dis Markers 30: 39-49.
37. Jain V, Armah HB, Tongren JE, Ned RM, Wilson NO, et al. (2008) Plasma IP-10, apoptotic and angiogenic factors associated with fatal cerebral malaria in India. Malar J 7: 83.
38. Armah HB, Wilson NO, Sarfo BY, Powell MD, Bond VC, et al. (2007) Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children. Malar J 6: 147.
39. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195-3204.
40. Asensio VC, Maier J, Milner R, Boztug K, Kincaid C, et al. (2001) Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol 75: 7067-7077.
41. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Bouwman F, et al. (2006) Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol 63: 538-543.
42. Lahrtz F, Piali L, Nadal D, Pfister HW, Spanaus KS, et al. (1997) Chemotactic activity on mononuclear cells in the cerebrospinal fluid of patients with viral meningitis is mediated by interferon-gamma inducible protein-10 and monocyte chemotactic protein-1. Eur J Immunol 27: 2484-2489.
43. Sui Y, Potula R, Pinson D, Adany I, Li Z, et al. (2003) Microarray analysis of cytokine and chemokine genes in the brains of macaques with SHIV-encephalitis. J Med Primatol 32: 229-239.
44. Campanella GS, Tager AM, El Khoury JK, Thomas SY, Abrazinski TA, et al. (2008) Chemokine receptor CXCR3 and its ligands CXCL9 and CXCL10 are required for the development of murine cerebral malaria. Proc Natl Acad Sci U S A 105: 4814-4819.
45. Grip O, Janciauskiene S, (2009) Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS One 4: e5263.
46. Goldstein JL, Brown MS, (2009) The LDL receptor. Arterioscler Thromb Vasc Biol 29: 431-438.
47. Hua Y, Xi G, Keep RF, Hoff JT, (2000) Complement activation in the brain after experimental intracerebral hemorrhage. J Neurosurg 92: 1016-1022.
48. Clemmer L, Martins YC, Zanini GM, Frangos JA, Carvalho LJ, (2011) Artemether and artesunate show the highest efficacies in rescuing mice with late-stage cerebral malaria and rapidly decrease leukocyte accumulation in the brain. Antimicrob Agents Chemother 55: 1383-1390.
49. Belnoue E, Kayibanda M, Vigario AM, Deschemin JC, van RN, et al. (2002) On the pathogenic role of brain-sequestered alphabeta CD8+ T cells in experimental cerebral malaria. J Immunol 169: 6369-6375.
50. Conroy AL, Lafferty EI, Lovegrove FE, Krudsood S, Tangpukdee N, et al. (2009) Whole blood angiopoietin-1 and-2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J 8: 295.
51. Conroy AL, Phiri H, Hawkes M, Glover S, Mallewa M, et al. (2010) Endothelium-based biomarkers are associated with cerebral malaria in Malawian children: a retrospective case-control study. PLoS One 5: e15291.
52. Jain V, Lucchi NW, Wilson NO, Blackstock AJ, Nagpal AC, et al. (2011) Plasma levels of angiopoietin-1 and-2 predict cerebral malaria outcome in Central India. Malar J 10: 383.
53. Lovegrove FE, Tangpukdee N, Opoka RO, Lafferty EI, Rajwans N, et al. (2009) Serum angiopoietin-1 and-2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One 4: e4912.
54. Potter S, Chaudhri G, Hansen A, Hunt NH, (1999) Fas and perforin contribute to the pathogenesis of murine cerebral malaria. Redox Rep 4: 333-335.
55. Potter SM, Chan-Ling T, Rosinova E, Ball HJ, Mitchell AJ, et al. (2006) A role for Fas-Fas ligand interactions during the late-stage neuropathological processes of experimental cerebral malaria. J Neuroimmunol 173: 96-107.
56. Moreno M, Ramalho LN, Sancho-Bru P, Ruiz-Ortega M, Ramalho F, et al. (2009) Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver. Am J Physiol Gastrointest Liver Physiol 296: G147-G156.
57. Qiu G, Hill JS, (2007) Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res 48: 2112-2122.
58. Li D, Chen H, Romeo F, Sawamura T, Saldeen T, et al. (2002) Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 302: 601-605.
59. Wagner AH, Schwabe O, Hecker M, (2002) Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 136: 143-149.
60. Zitvogel L, Kepp O, Kroemer G, (2010) Decoding cell death signals in inflammation and immunity. Cell 140: 798-804.
61. Gao HX, Campbell SR, Burkly LC, Jakubowski A, Jarchum I, et al. (2009) TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 46: 24-35.
62. Kanda N, Hau CS, Tada Y, Tatsuta A, Sato S, et al. (2011) Visfatin enhances CXCL8, CXCL10, and CCL20 production in human keratinocytes. Endocrinology 152: 3155-3164.
63. Liu P, Li K, Garofalo RP, Brasier AR, (2008) Respiratory syncytial virus induces RelA release from cytoplasmic 100-kDa NF-kappa B2 complexes via a novel retinoic acid-inducible gene-I{middle dot}NF- kappa B-inducing kinase signaling pathway. J Biol Chem 283: 23169-23178.
64. Penafuerte C, Bautista-Lopez N, Bouchentouf M, Birman E, Forner K, et al. (2011) Novel TGF-beta antagonist inhibits tumor growth and angiogenesis by inducing IL-2 receptor-driven STAT1 activation. J Immunol 186: 6933-6944.
65. Gorina R, Font-Nieves M, Marquez-Kisinousky L, Santalucia T, Planas AM, (2011) Astrocyte TLR4 activation induces a proinflammatory environment through the interplay between MyD88-dependent NFkappaB signaling, MAPK, and Jak1/Stat1 pathways. Glia 59: 242-255.
66. Ellis SL, Gysbers V, Manders PM, Li W, Hofer MJ, et al. (2010) The cell-specific induction of CXC chemokine ligand 9 mediated by IFN-gamma in microglia of the central nervous system is determined by the myeloid transcription factor PU.1. J Immunol 185: 1864-1877.
67. Vogel SN, Fenton M, (2003) Toll-like receptor 4 signalling: new perspectives on a complex signal-transduction problem. Biochem Soc Trans 31: 664-668.
68. Gueler F, Park JK, Rong S, Kirsch T, Lindschau C, et al. (2007) Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170: 1192-1199.
69. Drechsler Y, Dolganiuc A, Norkina O, Romics L, Li W, et al. (2006) Heme oxygenase-1 mediates the anti-inflammatory effects of acute alcohol on IL-10 induction involving p38 MAPK activation in monocytes. J Immunol 177: 2592-2600.
70. Vareille M, Rannou F, Thelier N, Glasser AL, de ST, et al. (2008) Heme oxygenase-1 is a critical regulator of nitric oxide production in enterohemorrhagic Escherichia coli-infected human enterocytes. J Immunol 180: 5720-5726.
71. Mandal P, Pratt BT, Barnes M, McMullen MR, Nagy LE, (2011) Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. J Biol Chem 286: 13460-13469.
72. Sasmazel A, Baysal A, Fedekar A, Buyukbayrak F, Bugra O, et al. (2010) The effect of statin therapy on stimulation of endothelium-derived nitric oxide before and after coronary artery bypass surgery. Heart Surg Forum 13: E243-E246.
73. Marshall HE, Stamler JS, (2002) Nitrosative stress-induced apoptosis through inhibition of NF-kappa B. J Biol Chem 277: 34223-34228.
74. Spiecker M, Peng HB, Liao JK, (1997) Inhibition of endothelial vascular cell adhesion molecule-1 expression by nitric oxide involves the induction and nuclear translocation of IkappaBalpha. J Biol Chem 272: 30969-30974.
75. Togashi H, Sasaki M, Frohman E, Taira E, Ratan RR, et al. (1997) Neuronal (type I) nitric oxide synthase regulates nuclear factor kappaB activity and immunologic (type II) nitric oxide synthase expression. Proc Natl Acad Sci U S A 94: 2676-2680.
76. Franek WR, Chowdary YC, Lin X, Hu M, Miller EJ, et al. (2002) Suppression of nuclear factor-kappa B activity by nitric oxide and hyperoxia in oxygen-resistant cells. J Biol Chem 277: 42694-42700.
77. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, et al. (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 104: 1041-1050.
78. Hemish J, Nakaya N, Mittal V, Enikolopov G, (2003) Nitric oxide activates diverse signaling pathways to regulate gene expression. J Biol Chem 278: 42321-42329.
79. Bouton C, Demple B, (2000) Nitric oxide-inducible expression of heme oxygenase-1 in human cells. Translation-independent stabilization of the mRNA and evidence for direct action of nitric oxide. J Biol Chem 275: 32688-32693.
80. Chen K, Maines MD, (2000) Nitric oxide induces heme oxygenase-1 via mitogen-activated protein kinases ERK and p38. Cell Mol Biol (Noisy-le-grand) 46: 609-617.
81. Liu M, Amodu AS, Pitts S, Patrickson J, Hibbert JM, et al. (2012) Heme Mediated STAT3 Activation in Severe Malaria. PLoS One 7: e34280.
82. Brown H, Rogerson S, Taylor T, Tembo M, Mwenechanya J, et al. (2001) Blood-brain barrier function in cerebral malaria in Malawian children. Am J Trop Med Hyg 64: 207-213.
83. Brown H, Hien TT, Day N, Mai NT, Chuong LV, et al. (1999) Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 25: 331-340.
84. Cordoliani YS, Sarrazin JL, Felten D, Caumes E, Leveque C, et al. (1998) MR of cerebral malaria. AJNR Am J Neuroradiol 19: 871-874.
85. Looareesuwan S, Wilairatana P, Krishna S, Kendall B, Vannaphan S, et al. (1995) Magnetic resonance imaging of the brain in patients with cerebral malaria. Clin Infect Dis 21: 300-309.
86. Millan JM, San Millan JM, Munoz M, Navas E, Lopez-Velez R, (1993) CNS complications in acute malaria: MR findings. AJNR Am J Neuroradiol 14: 493-494.
87. Patankar TF, Karnad DR, Shetty PG, Desai AP, Prasad SR, (2002) Adult cerebral malaria: prognostic importance of imaging findings and correlation with postmortem findings. Radiology 224: 811-816.
88. Haque A, Best SE, Unosson K, Amante FH, de LF, et al. (2011) Granzyme B expression by CD8+ T cells is required for the development of experimental cerebral malaria. J Immunol 186: 6148-6156.
89. Nitcheu J, Bonduelle O, Combadiere C, Tefit M, Seilhean D, et al. (2003) Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental cerebral malaria pathogenesis. J Immunol 170: 2221-2228.
90. Hunt NH, Golenser J, Chan-Ling T, Parekh S, Rae C, et al. (2006) Immunopathogenesis of cerebral malaria. Int J Parasitol 36: 569-582.
91. Deininger MH, Kremsner PG, Meyermann R, Schluesener H, (2002) Macrophages/microglial cells in patients with cerebral malaria. Eur Cytokine Netw 13: 173-185.
92. Schluesener HJ, Kremsner PG, Meyermann R, (1998) Widespread expression of MRP8 and MRP14 in human cerebral malaria by microglial cells. Acta Neuropathol 96: 575-580.
93. Medana IM, Hunt NH, Chan-Ling T, (1997) Early activation of microglia in the pathogenesis of fatal murine cerebral malaria. Glia 19: 91-103.
94. Medana IM, Chan-Ling T, Hunt NH, (1996) Redistribution and degeneration of retinal astrocytes in experimental murine cerebral malaria: relationship to disruption of the blood-retinal barrier. Glia 16: 51-64.
95. Jones KL, Donegan S, Lalloo DG (2007) Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev CD005967.
96. McIntosh HM, Olliaro P (2000) Artemisinin derivatives for treating severe malaria. Cochrane Database Syst Rev CD000527.
97. John CC, Opika-Opoka R, Byarugaba J, Idro R, Boivin MJ, (2006) Low levels of RANTES are associated with mortality in children with cerebral malaria. J Infect Dis 194: 837-845.
98. John CC, Panoskaltsis-Mortari A, Opoka RO, Park GS, Orchard PJ, et al. (2008) Cerebrospinal fluid cytokine levels and cognitive impairment in cerebral malaria. Am J Trop Med Hyg 78: 198-205.
99. Sarfo BY, Wilson NO, Bond VC, Stiles JK, (2011) Plasmodium berghei ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient C57BL/6 mice. Malar J 10: 69.
100. Souraud JB, Briolant S, Dormoi J, Mosnier J, Savini H, et al. (2012) Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model. Malar J 11: 13.
101. Helmers AJ, Gowda DC, Kain KC, Liles WC, (2009) Statins fail to improve outcome in experimental cerebral malaria and potentiate Toll-like receptor-mediated cytokine production by murine macrophages. Am J Trop Med Hyg 81: 631-637.
102. Kobbe R, Schreiber N, May J, Jacobs T, (2008) Simvastatin treatment shows no effect on the incidence of cerebral malaria or parasitemia during experimental malaria. Antimicrob Agents Chemother 52: 1583-1584.
103. Bienvenu AL, Picot S, (2008) Statins alone are ineffective in cerebral malaria but potentiate artesunate. Antimicrob Agents Chemother 52: 4203-4204.
104. Reis PA, Estato V, da Silva TI, d'Avila JC, Siqueira LD, et al. (2012) Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog 8: e1003099.
105. Taylor TE, Fu WJ, Carr RA, Whitten RO, Mueller JS, et al. (2004) Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 10: 143-145.
106. Hansen DS, (2012) Inflammatory responses associated with the induction of cerebral malaria: lessons from experimental murine models. PLoS Pathog 8: e1003045.
107. Ochiel DO, Awandare GA, Keller CC, Hittner JB, Kremsner PG, et al. (2005) Differential regulation of beta-chemokines in children with Plasmodium falciparum malaria. Infect Immun 73: 4190-4197.
108. Hearn J, Rayment N, Landon DN, Katz DR, de Souza JB, (2000) Immunopathology of cerebral malaria: morphological evidence of parasite sequestration in murine brain microvasculature. Infect Immun 68: 5364-5376.
109. Widenfalk J, Lipson A, Jubran M, Hofstetter C, Ebendal T, et al. (2003) Vascular endothelial growth factor improves functional outcome and decreases secondary degeneration in experimental spinal cord contusion injury. Neuroscience 120: 951-960.
110. Krum JM, Khaibullina A, (2003) Inhibition of endogenous VEGF impedes revascularization and astroglial proliferation: roles for VEGF in brain repair. Exp Neurol 181: 241-257.
111. Gay F, Zougbede S, N'dilimabaka N, Rebollo A, Mazier D, Moreno A, (2012) Cerebral malaria: what is known and what is on research. Rev Neurol (Paris) 168: 239-256.
112. Mehta D, Malik AB, (2006) Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367.
113. van Nieuw Amerongen GP, van H, (2002) V (2002) Targets for pharmacological intervention of endothelial hyperpermeability and function. Vascul Pharmacol 39: 257-272.
114. Conroy, Glover SJ, Hawkes M, Erdman LK, Seydel KB, et al. (2012) Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study*. Crit Care Med 40: 952-959.
115. Erdman LK, Dhabangi A, Musoke C, Conroy AL, Hawkes M, et al. (2011) Combinations of host biomarkers predict mortality among Ugandan children with severe malaria: a retrospective case-control study. PLoS One 6: e17440.
116. Schofield L, Grau GE, (2005) Immunological processes in malaria pathogenesis. Nat Rev Immunol 5: 722-735.
117. Chakravorty SJ, Craig A, (2005) The role of ICAM-1 in Plasmodium falciparum cytoadherence. Eur J Cell Biol 84: 15-27.
118. Dietrich JB, (2002) The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol 128: 58-68.
119. Ochola LB, Siddondo BR, Ocholla H, Nkya S, Kimani EN, et al. (2011) Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS One 6: e14741.
120. Armah H, Dodoo AK, Wiredu EK, Stiles JK, Adjei AA, et al. (2005) High-level cerebellar expression of cytokines and adhesion molecules in fatal, paediatric, cerebral malaria. Ann Trop Med Parasitol 99: 629-647.
121. Cserti-Gazdewich CM, Dzik WH, Erdman L, Ssewanyana I, Dhabangi A, et al. (2010) Combined measurement of soluble and cellular ICAM-1 among children with Plasmodium falciparum malaria in Uganda. Malar J 9: 233.
122. Patnaik JK, Das BS, Mishra SK, Mohanty S, Satpathy SK, et al. (1994) Vascular clogging, mononuclear cell margination, and enhanced vascular permeability in the pathogenesis of human cerebral malaria. Am J Trop Med Hyg 51: 642-647.
123. Li J, Chang WL, Sun G, Chen HL, Specian RD, et al. (2003) Intercellular adhesion molecule 1 is important for the development of severe experimental malaria but is not required for leukocyte adhesion in the brain. J Investig Med 51: 128-140.
124. Grau GE, Pointaire P, Piguet PF, Vesin C, Rosen H, et al. (1991) Late administration of monoclonal antibody to leukocyte function-antigen 1 abrogates incipient murine cerebral malaria. Eur J Immunol 21: 2265-2267.
125. Lawson C, Wolf S, (2009) ICAM-1 signaling in endothelial cells. Pharmacol Rep 61: 22-32.
126. Sumagin R, Lomakina E, Sarelius IH, (2008) Leukocyte-endothelial cell interactions are linked to vascular permeability via ICAM-1-mediated signaling. Am J Physiol Heart Circ Physiol 295: H969-H977.
127. Etienne-Manneville S, Manneville JB, Adamson P, Wilbourn B, Greenwood J, et al. (2000) ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol 165: 3375-3383.
128. Miu J, Mitchell AJ, Muller M, Carter SL, Manders PM, et al. (2008) Chemokine gene expression during fatal murine cerebral malaria and protection due to CXCR3 deficiency. J Immunol 180: 1217-1230.
129. Potter S, Chan-Ling T, Ball HJ, Mansour H, Mitchell A, et al. (2006) Perforin mediated apoptosis of cerebral microvascular endothelial cells during experimental cerebral malaria. Int J Parasitol 36: 485-496.
130. Turner GD, Morrison H, Jones M, Davis TM, Looareesuwan S, et al. (1994) An immunohistochemical study of the pathology of fatal malaria. Evidence for widespread endothelial activation and a potential role for intercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 145: 1057-1069.
131. Aikawa M, Iseki M, Barnwell JW, Taylor D, Oo MM, et al. (1990) The pathology of human cerebral malaria. Am J Trop Med Hyg 43: 30-37.
132. Ahlqvist J, (1985) Decreased red cell deformability and vascular obstruction in falciparum malaria illustrated by a fatal case. Scand J Haematol 35: 531-535.
133. Lyke KE, Burges R, Cissoko Y, Sangare L, Dao M, et al. (2004) Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. Infect Immun 72: 5630-5637.
134. Achtman AH, Pilat S, Law CW, Lynn DJ, Janot L, et al. (2012) Effective adjunctive therapy by an innate defense regulatory Peptide in a preclinical model of severe malaria. Sci Transl Med 4: 135ra64.
135. Grau GE, Heremans H, Piguet PF, Pointaire P, Lambert PH, et al. (1989) Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. Proc Natl Acad Sci U S A 86: 5572-5574.
136. Grau GE, Taylor TE, Molyneux ME, Wirima JJ, Vassalli P, et al. (1989) Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 320: 1586-1591.
137. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, et al. (1996) The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 174: 1091-1097.
138. Jakobsen PH, McKay V, Morris-Jones SD, McGuire W, van Hensbroek MB, et al. (1994) Increased concentrations of interleukin-6 and interleukin-1 receptor antagonist and decreased concentrations of beta-2-glycoprotein I in Gambian children with cerebral malaria. Infect Immun 62: 4374-4379.
139. Kern P, Hemmer CJ, Van DJ, Gruss HJ, Dietrich M, (1989) Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 87: 139-143.
140. Mshana RN, Boulandi J, Mshana NM, Mayombo J, Mendome G, (1991) Cytokines in the pathogenesis of malaria: levels of IL-I beta, IL-4, IL-6, TNF-alpha and IFN-gamma in plasma of healthy individuals and malaria patients in a holoendemic area. J Clin Lab Immunol 34: 131-139.
141. Wenisch C, Linnau KF, Looaresuwan S, Rumpold H, (1999) Plasma levels of the interleukin-6 cytokine family in persons with severe Plasmodium falciparum malaria. J Infect Dis 179: 747-750.
142. Stamatovic SM, Shakui P, Keep RF, Moore BB, Kunkel SL, et al. (2005) Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 25: 593-606.
143. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV, (2003) Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase. J Cell Sci 116: 4615-4628.
144. Owens T, Renno T, Taupin V, Krakowski M, (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15: 566-571.
145. Yamagami S, Tamura M, Hayashi M, Endo N, Tanabe H, et al. (1999) Differential production of MCP-1 and cytokine-induced neutrophil chemoattractant in the ischemic brain after transient focal ischemia in rats. J Leukoc Biol 65: 744-749.
146. Cinque P, Vago L, Mengozzi M, Torri V, Ceresa D, et al. (1998) Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS 12: 1327-1332.
147. Sarfo BY, Singh S, Lillard JW Jr, Quarshie A, Gyasi RK, et al. (2004) The cerebral-malaria-associated expression of RANTES, CCR3 and CCR5 in post-mortem tissue samples. Ann Trop Med Parasitol 98: 297-303.
148. Awandare GA, Goka B, Boeuf P, Tetteh JK, Kurtzhals JA, et al. (2006) Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis 194: 1438-1446.
149. Sarthou JL, Angel G, Aribot G, Rogier C, Dieye A, et al. (1997) Prognostic value of anti-Plasmodium falciparum-specific immunoglobulin G3, cytokines, and their soluble receptors in West African patients with severe malaria. Infect Immun 65: 3271-3276.
150. Peyron F, Burdin N, Ringwald P, Vuillez JP, Rousset F, et al. (1994) High levels of circulating IL-10 in human malaria. Clin Exp Immunol 95: 300-303.
151. Eckwalanga M, Marussig M, Tavares MD, Bouanga JC, Hulier E, et al. (1994) Murine AIDS protects mice against experimental cerebral malaria: down-regulation by interleukin 10 of a T-helper type 1 CD4+ cell-mediated pathology. Proc Natl Acad Sci U S A 91: 8097-8101.
152. Idro R, Carter JA, Fegan G, Neville BG, Newton CR, (2006) Risk factors for persisting neurological and cognitive impairments following cerebral malaria. Arch Dis Child 91: 142-148.
153. Schijns OE, Visser-Vandewalle V, Lemmens EM, Janssen A, Hoogland G, (2008) Surgery for temporal lobe epilepsy after cerebral malaria. Seizure 17: 731-734.
154. Grote CL, Pierre-Louis SJ, Durward WF, (1997) Deficits in delayed memory following cerebral malaria: a case study. Cortex 33: 385-388.
155. Wen TC, Tanaka J, Peng H, Desaki J, Matsuda S, et al. (1998) Interleukin 3 prevents delayed neuronal death in the hippocampal CA1 field. J Exp Med 188: 635-649.
156. Zambrano A, Otth C, Mujica L, Concha II, Maccioni RB, (2007) Interleukin-3 prevents neuronal death induced by amyloid peptide. BMC Neurosci 8: 82.
157. Gomez-Nicola D, Valle-Argos B, Suardiaz M, Taylor JS, Nieto-Sampedro M, (2008) Role of IL-15 in spinal cord and sciatic nerve after chronic constriction injury: regulation of macrophage and T-cell infiltration. J Neurochem 107: 1741-1752.
158. Huang Z, Ha GK, Petitto JM, (2007) IL-15 and IL-15R alpha gene deletion: effects on T lymphocyte trafficking and the microglial and neuronal responses to facial nerve axotomy. Neurosci Lett 417: 160-164.
159. Rentzos M, Rombos A, (2012) The role of IL-15 in central nervous system disorders. Acta Neurol Scand 125: 77-82.
160. Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, et al. (2006) Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 113: 701-710.
161. Lee ST, Chu K, Jung KH, Ko SY, Kim EH, et al. (2005) Granulocyte colony-stimulating factor enhances angiogenesis after focal cerebral ischemia. Brain Res 1058: 120-128.
162. Schneider A, Kruger C, Steigleder T, Weber D, Pitzer C, et al. (2005) The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 115: 2083-2098.
163. Saito M, Kiyokawa N, Taguchi T, Suzuki K, Sekino T, et al. (2002) Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol 30: 1115-1123.
164. Diederich K, Schabitz WR, Minnerup J, (2012) Seeing old friends from a different angle: novel properties of hematopoietic growth factors in the healthy and diseased brain. Hippocampus 22: 1051-1057.
165. Nishio Y, Koda M, Kamada T, Someya Y, Kadota R, et al. (2007) Granulocyte colony-stimulating factor attenuates neuronal death and promotes functional recovery after spinal cord injury in mice. J Neuropathol Exp Neurol 66: 724-731.
166. Pamplona A, Ferreira A, Balla J, Jeney V, Balla G, et al. (2007) Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat Med 13: 703-710.
167. Ali F, Zakkar M, Karu K, Lidington EA, Hamdulay SS, et al. (2009) Induction of the cytoprotective enzyme heme oxygenase-1 by statins is enhanced in vascular endothelium exposed to laminar shear stress and impaired by disturbed flow. J Biol Chem 284: 18882-18892.
168. Nath N, Giri S, Prasad R, Singh AK, Singh I, (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172: 1273-1286.
169. Cabrales P, Zanini GM, Meays D, Frangos JA, Carvalho LJ, (2011) Nitric oxide protection against murine cerebral malaria is associated with improved cerebral microcirculatory physiology. J Infect Dis 203: 1454-1463.
170. Hawkes M, Opoka RO, Namasopo S, Miller C, Conroy AL, et al. (2011) Nitric oxide for the adjunctive treatment of severe malaria: hypothesis and rationale. Med Hypotheses 77: 437-444.
171. Martins YC, Zanini GM, Frangos JA, Carvalho LJ, (2012) Efficacy of different nitric oxide-based strategies in preventing experimental cerebral malaria by Plasmodium berghei ANKA. PLoS One 7: e32048.
172. Serghides L, Kim H, Lu Z, Kain DC, Miller C, et al. (2011) Inhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malaria. PLoS One 6: e27714.
173. Stein EA, (2007) Statins and children: whom do we treat and when? Circulation 116: 594-595.
174. Carreau V, Girardet JP, Bruckert E, (2011) Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability. Paediatr Drugs 13: 267-275.
175. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, et al. (2010) Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev CD006401.
176. Wierzbicki AS, Viljoen A, (2010) Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice. Drug Saf 33: 115-125.
177. Lackner P, Beer R, Heussler V, Goebel G, Rudzki D, et al. (2006) Behavioural and histopathological alterations in mice with cerebral malaria. Neuropathol Appl Neurobiol 32: 177-188.
178. Martins YC, Werneck GL, Carvalho LJ, Silva BP, Andrade BG, et al. (2010) Algorithms to predict cerebral malaria in murine models using the SHIRPA protocol. Malar J 9: 85.
179. Waknine-Grinberg JH, Hunt N, tura-Marciano A, McQuillan JA, Chan HW, et al. (2010) Artemisone effective against murine cerebral malaria. Malar J 9: 227.